In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.
Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial that showed the triple combination therapy PT010 outperformed dual-therapy rivals eight of nine times.
China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.